FDA approves Novartis's Cosentyx for polymyalgia rheumatica, the first IL-17 drug for the disease

The FDA approved Novartis's Cosentyx 150 mg for polymyalgia rheumatica (PMR) in adults who do not respond to steroids or cannot tolerate tapering. The approval was based on the REPLENISH trial, where 40.5% of patients achieved sustained remission compared to 20.5% on placebo. Cosentyx sales were $1.857 billion in Q3, up 9% at constant currency.

Original reporting
Published Nov 18, 2026, 5:07 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 5:56 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$NVS
Bullish
high confidence
Mentioned
$NVS
Relevance
7/10
AlphAI data visualization · based on mlq.ai
Decision brief

The 30-second read

$NVSBullishHigh
01

Why it matters

The approval provides a new revenue stream and may lift Novartis's stock as investors price in the expanded market.

02

Market read

Regulatory approval of a major drug adds material upside potential for Novartis and signals broader interest in IL‑17 therapies.

03

What to watch

Reimbursement negotiations and pricing uncertainty for the new PMR indication.

Relevance 7/10Novelty 9/10Timing: today

Background

Novartis announced FDA approval of its IL‑17 biologic Cosentyx for polymyalgia rheumatica, expanding the drug to its 11th U.S. indication.

Company-level read

Ticker impact

$NVSBullishHigh confidence
Context

FDA approved Novartis's Cosentyx 150 mg for polymyalgia rheumatica, the first IL‑17 drug for the disease.

Expected impact

upward pressure as investors price in expanded market opportunity for Cosentyx.

Evidence & confidence

Regulatory approval is a primary catalyst; the drug already generates $1.9 B in Q3 sales and the new indication opens a sizable US patient base.

Market effects

Strengthens biotech and pharma sector, especially companies with IL‑17 pipelines.

U.S. equities likely see a modest lift, particularly healthcare indexes.

Global markets may react as the indication is approved in the EU and under review in Japan.

Counterpoint

Potential safety concerns and competition from existing IL‑6 therapy Kevzara could limit uptake.

Key entities

  • Novartis AG

    Swiss pharmaceutical company, ticker NVS.

  • Cosentyx (secukinumab)

    IL‑17A inhibitor now approved for PMR.

Related articles

$NVSMed

FDA Approves Secukinumab as First Anti–IL-17 Biologic for PMR

The FDA approved a 150-mg dose of secukinumab (Cosentyx, Novartis) for polymyalgia rheumatica (PMR), making it the first anti-IL-17 biologic for this condition. The approval was based on the phase 3 REPLENISH trial, which showed higher remission rates with secukinumab plus a glucocorticoid taper compared to the taper alone. According to Novartis, this is the 11th US indication for secukinumab.

$NVSMed

Cosentyx Wins FDA Approval for Polymyalgia Rheumatica Patients Who Cannot Taper Steroids, Doubling Sustained Remission in Trial

Novartis' Cosentyx (secukinumab) 150 mg received FDA approval for polymyalgia rheumatica in patients who cannot taper steroids. The approval follows a trial where 40.5% of patients on Cosentyx achieved sustained remission at one year, compared to 20.5% on placebo. Cosentyx is the first IL-17 blocking biologic approved for this condition, according to Novartis.

$NVSMed

Novartis reports positive phase 3 data on ianalumab for Sjögren’s

Novartis reported positive long-term phase 3 data for ianalumab in Sjögren’s disease, showing improved disease activity and a favorable safety profile. The FDA granted Breakthrough Therapy Designation in January, with a decision expected this year. Ianalumab is also being investigated for other autoimmune diseases. Novartis aims to address the unmet need for disease-modifying treatments in Sjögren’s.

$NVSMed

FDA Clears Secukinumab for Use in Polymyalgia Rheumatica

The FDA approved Novartis' secukinumab (Cosentyx) for treating polymyalgia rheumatica (PMR) in adults unresponsive to corticosteroids. The approval follows positive phase 3 REPLENISH trial results, showing sustained remission rates of 41.2% and 40.6% for 300 mg and 150 mg doses, respectively, compared to 20.4% for placebo. Secukinumab is already approved for several other inflammatory conditions.

$NVSMed

FDA Approves Secukinumab as First IL-17 Biologic for Polymyalgia Rheumatica

The FDA approved Novartis' secukinumab (Cosentyx) 150 mg for polymyalgia rheumatica (PMR) in adults with inadequate corticosteroid response. The approval follows phase 3 trial results showing sustained remission in 40.5% of patients vs. 20.5% on placebo. Secukinumab is the first IL-17 biologic approved for PMR, offering a new treatment option with a steroid-sparing effect.